OptimizeRx Corporation disclosed the departure of its Chief Commercial Officer, Theresa Greco, effective June 15, 2026. The company entered into a Separation and Advisory Agreement with Ms. Greco on June 1, 2026, outlining the terms of her separation, severance package, and a subsequent 12-month advisory role.

Key Details

  • Executive Departure: Theresa Greco will cease serving as Chief Commercial Officer effective June 15, 2026.
  • Separation Package: Ms. Greco will receive 12 months of her $380,000 base salary, a lump sum bonus payment of $209,000, and 12 months of COBRA premium reimbursements.
  • Advisory Agreement: Ms. Greco will provide advisory services through June 15, 2027, during which time her previously granted equity will continue to vest. She is also subject to a 12-month non-compete and non-solicitation agreement.